Erste Asset Management Gmb H Sangamo Therapeutics, Inc Transaction History

Erste Asset Management Gmb H

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 26, 2024	BUY	$4.27 - $6.39 $162,259 - $242,820	38,000 New	38,000 $185 Million
Q2 2022 Nov 26, 2024	BUY	$3.28 - $6.21 $6,560 - $12,420	2,000 Added 5.56%	38,000 $157 Million
Q4 2021 Nov 22, 2024	BUY	$7.29 - $10.97 $277,020 - $416,860	38,000 New	38,000 $301 Million
Q4 2020 Nov 22, 2024	BUY	$9.23 - $18.18 $18,460 - $36,360	2,000 Added 5.56%	38,000 $632 Million
Q3 2020 Nov 22, 2024	BUY	$9.38 - $12.48 $337,680 - $449,280	36,000 New	36,000 $356 Million
Q4 2019 Nov 22, 2024	BUY	$8.03 - $11.7 $289,080 - $421,200	36,000 New	36,000 $301 Million
Q1 2019 Nov 22, 2024	BUY	$7.72 - $12.81 $277,920 - $461,160	36,000 New	36,000 $336 Million
Q4 2018 Nov 26, 2024	BUY	$9.51 - $16.6 $342,360 - $597,600	36,000 New	36,000 $381 Million

111

56.7M

576K

1.17M

Ticker SGMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 156,552,992
Market Cap $193M
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.